Develops oral small-molecule therapies that target a cell-signaling protein for people with inflammatory and proliferative diseases.
10-K for FY2025, filed Mar 31, 2026
From itch treatments to targeted therapies
The older report centers on an injection and oral treatment for chronic itch; the latest centers on oral inhibitors of a signaling protein for inflammatory and proliferative diseases.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 31, 2026We are a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from…View ↗
Expanding our Nephrology Franchise by optimizing the commercial potential of KORSUVA injection and developing oral difelikefalin for the…View ↗
Our Dermatology Franchise is focused on developing oral difelikefalin in pruritus associated with AD and NP, two complementary indications…View ↗
Competes with Moleculin Biotech, Purple Biotech, and Scopus BioPharma
10-K for FY2025, filed Mar 31, 2026There are a number of large biopharmaceutical and biotechnology companies that are currently pursuing the development of products for the…View ↗
Loading...